Skip to content
Home / Companies / RXRX RXR
RECURSION PHARMACEUTICALS, INC. (RXRX) XNAS BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Net insider selling (90d)
Latest RXRX Insider Trades
About RECURSION PHARMACEUTICALS, INC. (RXRX) Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Headquarters SALT LAKE CITY, UT
Employees 600
Listed 2021
Exchange XNAS https://www.recursion.com SEC filings for RXRX on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 7 171,937 $624K Grant or award 9 627,824 Tax withholding / forfeiture 4 137,569
RXRX Insider Transactions (Form 4) 82 90 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 3 of 3.
Date Insider Transaction Security Shares Price Value Sep 15, 2025 BT Ben R. Taylor - Officer Tax withholding / forfeiture Class A Common Stock 7,057
Recent RXRX Form 8-K Filings 5
Recent RXRX Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 21, 2026 Gibson Christopher Former Director 77,290 $262K View on EDGAR Aug 20, 2026 Gibson Christopher Former Director
RXRX Insider Trading - FAQ
What is the latest insider trade for RXRX? RECURSION PHARMACEUTICALS, INC. (RXRX) had 19 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for RXRX runs to 90 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying RXRX stock? No insider purchases of RXRX were filed in the last 90 days.
How many insiders are selling RXRX stock? 7 insider sales of RXRX were filed in the last 90 days, totaling $624K.
Where can I see RXRX SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks RXRX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow RXRX insider buys? Create a free InsiderAlpha account and press Watch on this page to add RXRX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track RXRX insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free Jul 7, 2026
NK Najat Khan - Officer Open-market sale $84K
Jun 5, 2026
Market cap $1.79B
P/E ratio -
Dividend yield -
Average volume 20.34M
52 week high $7.18
52 week low $2.77
Today's high $3.45
Today's low $3.31
Open $3.40
Volume 10.56M
Previous close $3.44
Shares outstanding 536.27M Market cap
$1.79B
600 employees
RXRX Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 7 sales totaling $624K.
Most-Active RXRX Insiders - Last 90 Days 10 Other acquisition / disposition 2 80,000
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Sep 10, 2025 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 100,000 $4.71 $471K
Aug 26, 2025 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 100,000 $4.84 $484K
Aug 15, 2025 NK Najat Khan - Officer Tax withholding / forfeiture Class A Common Stock 3,789 $5.64 $21K
Aug 18, 2025 NK Najat Khan - Officer Open-market sale Class A Common Stock 36,599 $5.52 $202K
Aug 15, 2025 BT Ben R. Taylor - Officer Tax withholding / forfeiture Class A Common Stock 11,908 $5.64 $67K
Aug 15, 2025 CG Christopher Gibson - Officer Tax withholding / forfeiture Class A Common Stock 40,390 $5.64 $228K
Aug 11, 2025 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 500,300 $5.28 $2.64M
Aug 11, 2025 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 100,000 $5.28 $528K
Aug 11, 2025 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 17,875 $5.28 $94K
Jul 1, 2025 DL Dean Y. Li - Director Grant or award Class A Common Stock 1,949 $0.00 -
Jul 1, 2025 ZD Zavain Dar - Director Grant or award Class A Common Stock 2,924 $0.00 -
Jun 18, 2025 RH Robert Hershberg - Director Grant or award Class A Common Stock 22,016 $0.00 -
Jun 18, 2025 RH Robert Hershberg - Director Grant or award Stock Option (Right to Buy) 44,031 $0.00 -
Dec 19, 2024 BT Ben R. Taylor - Officer Grant or award Class A Common Stock 370,343 $0.00 -
Dec 19, 2024 BT Ben R. Taylor - Officer Grant or award Stock Option (Right to Buy) 740,686 $0.00 -
Dec 16, 2024 BT Ben R. Taylor - Officer Tax withholding / forfeiture Class A Common Stock 15,668 $6.04 $95K
Dec 17, 2024 BT Ben R. Taylor - Officer Tax withholding / forfeiture Class A Common Stock 7,057 $6.95 $49K
Dec 4, 2024 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 20,000 $7.16 $143K
Dec 5, 2024 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 20,000 $7.12 $142K
Nov 20, 2024 FM Franziska Michor - Director Grant or award Class A Common Stock 30,618 - -
Nov 20, 2024 FM Franziska Michor - Director Grant or award Class A Common Stock 15,335 $0.00 -
Nov 20, 2024 FM Franziska Michor - Director Grant or award Class A Common Stock 17,694 $0.00 -
Nov 20, 2024 FM Franziska Michor - Director Grant or award Class A Common Stock 41,390 $0.00 -
Nov 20, 2024 FM Franziska Michor - Director Grant or award Stock Option (Right to Buy) 30,670 - -
Nov 20, 2024 FM Franziska Michor - Director Grant or award Stock Option (Right to Buy) 15,286 - -
Nov 20, 2024 FM Franziska Michor - Director Grant or award Stock Option (Right to Buy) 17,694 - -
Nov 20, 2024 FM Franziska Michor - Director Grant or award Stock Option (Right to Buy) 82,781 $0.00 -
Nov 15, 2024 MS Michael Secora - Officer Tax withholding / forfeiture Class A Common Stock 11,937 $6.18 $74K
Nov 15, 2024 TM Tina Marriott - Officer Tax withholding / forfeiture Class A Common Stock 14,286 $6.18 $88K
Nov 15, 2024 CG Christopher Gibson - Officer Tax withholding / forfeiture Class A Common Stock 26,023 $6.18 $161K
Nov 15, 2024 DM David J. Mauro - Officer Tax withholding / forfeiture Class A Common Stock 4,187 $6.18 $26K
Nov 13, 2024 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 20,000 $7.74 $155K
Nov 14, 2024 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 20,000 $7.35 $147K
Nov 12, 2024 MS Michael Secora - Officer Option exercise Class A Common Stock 39,375 $2.22 $87K
Nov 12, 2024 MS Michael Secora - Officer Open-market sale Class A Common Stock 15,000 $7.64 $115K
Nov 13, 2024 MS Michael Secora - Officer Option exercise Class A Common Stock 39,375 $2.22 $87K
Nov 13, 2024 MS Michael Secora - Officer Open-market sale Class A Common Stock 15,000 $7.66 $115K
Nov 12, 2024 MS Michael Secora - Officer Option exercise Stock Option (Right to Buy) 39,375 $0.00 -
Nov 13, 2024 MS Michael Secora - Officer Option exercise Stock Option (Right to Buy) 39,375 $0.00 -
Nov 12, 2024 BB Blake Borgeson - Director Open-market sale Class A Common Stock 11,447 $7.64 $87K
Oct 29, 2024 BB Blake Borgeson - Director Open-market sale Class A Common Stock 11,447 $6.72 $77K
Oct 24, 2024 TM Tina Marriott - Officer Option exercise Class A Common Stock 6,000 $1.06 $6K
Oct 24, 2024 TM Tina Marriott - Officer Open-market sale Class A Common Stock 6,000 $6.31 $38K
Oct 24, 2024 TM Tina Marriott - Officer Option exercise Stock Option (Right to Buy) 6,000 $0.00 -
Oct 15, 2024 BB Blake Borgeson - Director Open-market sale Class A Common Stock 11,447 $6.67 $76K
Oct 8, 2024 MS Michael Secora - Officer Option exercise Class A Common Stock 39,375 $2.22 $87K
Oct 8, 2024 MS Michael Secora - Officer Open-market sale Class A Common Stock 15,000 $6.32 $95K
Oct 9, 2024 MS Michael Secora - Officer Option exercise Class A Common Stock 39,375 $2.22 $87K
Oct 9, 2024 MS Michael Secora - Officer Open-market sale Class A Common Stock 15,000 $6.36 $95K
Oct 8, 2024 MS Michael Secora - Officer Option exercise Stock Option (Right to Buy) 39,375 $0.00 -
Oct 9, 2024 MS Michael Secora - Officer Option exercise Stock Option (Right to Buy) 39,375 $0.00 -
Oct 2, 2024 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 20,000 $6.16 $123K
Oct 3, 2024 CG Christopher Gibson - Officer Open-market sale Class A Common Stock 20,000 $6.08 $122K
Oct 1, 2024 DL Dean Y. Li - Director Grant or award Class A Common Stock 1,925 $0.00 -
Oct 1, 2024 ZD Zavain Dar - Director Grant or award Class A Common Stock 2,229 $0.00 -
Oct 1, 2024 BB Blake Borgeson - Director Grant or award Class A Common Stock 2,026 $0.00 -
Oct 1, 2024 BB Blake Borgeson - Director Open-market sale Class A Common Stock 11,447 $6.22 $71K
Aug 19, 2026 Gibson Christopher Former Director 100,000 $328K View on EDGAR
